Prelude Therapeutics initiates PRT13722 Phase 1 trial for breast cancer
Prelude Therapeutics reported Q3 2026 financial results and announced enrollment has begun for its first oral KAT6A degrader, PRT13722, in breast cancer, with data expected in late 2027. The company also announced a collaboration with Eli Lilly and has $142.7 million in cash runway extending through Q2 2028.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed